Effects of long-term use of the preferential COX-2 inhibitor meloxicam on growing pigs

被引:8
|
作者
Gorissen, Ben M. C. [1 ]
Uilenreef, Joost J. [2 ]
Bergmann, Wilhelmina [3 ]
Meijer, Ellen [4 ]
van Rietbergen, Bert [5 ]
van der Staay, Franz Josef [4 ]
van Weeren, P. Rene [6 ]
Wolschrijn, Claudia F. [1 ]
机构
[1] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Anat & Physiol Div, Utrecht, Netherlands
[2] Univ Utrecht, Fac Vet Med, Anaesthesiol Div, Dept Clin Sci Compan Anim, Utrecht, Netherlands
[3] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Div Pathol, Utrecht, Netherlands
[4] Univ Utrecht, Fac Vet Med, Behav & Welf Grp, Dept Farm Anim Hlth, Utrecht, Netherlands
[5] Eindhoven Univ Technol, Orthopaed Biomech Div, Dept Biomed Engn, Eindhoven, Netherlands
[6] Univ Utrecht, Fac Vet Med, Dept Equine Sci, Utrecht, Netherlands
关键词
TRABECULAR BONE; PRESSURE PLATE; RENAL-FUNCTION; PREGNANT SOWS; LAMENESS; ASSOCIATIONS; WELFARE; JOINT; PAIN; PHARMACOKINETICS;
D O I
10.1136/vr.104175
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Meloxicam, a preferential COX-2 inhibitor, is a commonly used NSAID in pigs. Besides having potential side effects on the gastrointestinal tract, this type of drug might potentially affect osteogenesis and chondrogenesis, processes relevant to growing pigs. Therefore, the effects of long-term meloxicam treatment on growing pigs were studied. Twelve piglets (n=6 receiving daily meloxicam 0.4 mg/kg orally from 48 until 110 days of age; n=6 receiving only applesauce (vehicle control)) were subjected to visual and objective gait analysis by pressure plate measurements at several time points. Following euthanasia a complete postmortem examination was performed and samples of the talus and distal tibia, including the distal physis, were collected. Trabecular bone microarchitecture was analysed by microCT scanning, bone stiffness by compression testing and growth plate morphology using light microscopy. Animals were not lame and gait patterns did not differ between the groups. Pathological examination revealed no lesions compatible with known side effects of NSAIDs. Trabecular bone microarchitecture and growth plate morphology did not differ between the two groups. The findings of this in vivo study reduce concerns regarding the long-term use of meloxicam in young, growing piglets.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Long-term effects of a COX-2 inhibitor on esophageal mucosal epithelial cell proliferation of patients with Barrett's esophagus: Preliminary results of a randomized controlled trial
    Lanas, A
    Ortego, J
    Sopena, F
    Bujanda, L
    Cosme, A
    Pique, JM
    Parra-Blanco, A
    Alcedo, J
    Ferrandez, A
    Quintero, E
    GASTROENTEROLOGY, 2004, 126 (04) : A25 - A25
  • [42] Effects of systemic COX-2 inhibitor therapy on intraocular pressure
    Wadia, HP
    Realini, T
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U451 - U451
  • [43] Dual effects of nimesulide, a COX-2 inhibitor, in human platelets
    Saeed, SA
    Afzal, MN
    Shah, BH
    LIFE SCIENCES, 1998, 63 (20) : 1835 - 1841
  • [44] Long-term intermittent oral administration of selective COX-2 inhibitor improved the clinical outcomes of COVID-19 in patients with cirrhosis
    Chen, Ming
    Yang, Zhu
    Gong, Hui
    Wu, Hao
    Liu, Ling
    Jiang, Jing Sun
    Gao, Jin Hang
    Tang, Cheng Wei
    Huang, Zhi Yin
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (08) : 517 - 524
  • [45] Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension
    Widlansky, ME
    Price, DT
    Gokce, N
    Eberhardt, RT
    Duffy, SJ
    Holbrook, M
    Maxwell, C
    Palmisano, J
    Keaney, JF
    Morrow, JD
    Vita, JA
    HYPERTENSION, 2003, 42 (03) : 310 - 315
  • [46] Potential use of COX-2–aromatase inhibitor combinations in breast cancer
    N J Bundred
    N L P Barnes
    British Journal of Cancer, 2005, 93 : S10 - S15
  • [47] The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy
    Yood, Marianne Ulcickas
    Watkins, Emmeline
    Wells, Karen
    Kucera, Gena
    Johnson, Christine Cole
    Lydick, Eva
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (12) : 852 - 860
  • [48] Meloxicam, a COX-2 Inhibitor, Ameliorates Ischemia/Reperfusion Injury in Non-Heart-Beating Donor Livers
    Stoffels, B.
    Yonezawa, K.
    Yamamoto, Y.
    Schaefer, N.
    Overhaus, M.
    Klinge, U.
    Kalff, J. C.
    Minor, T.
    Tolba, R. H.
    EUROPEAN SURGICAL RESEARCH, 2011, 47 (03) : 109 - 117
  • [49] Phase II trial of meloxicam, a COX-2 inhibitor, and interferon alfa in patients with metastatic renal cell carcinoma
    Shinohara, N.
    Abe, T.
    Sazawa, A.
    Nonomura, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Side Effects of Long-Term Proton Pump Inhibitor Use: A Review
    Haastrup, Peter Fentz
    Thompson, Wade
    Sondergaard, Jens
    Jarbol, Dorte Ejg
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (02) : 114 - 121